The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations
Official Title: A Multi-center, Randomized, Parallel Group, Double-blind, Vehicle-controlled Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, 0.05%, In Patients With Actinic Keratoses on Non-head Locations (REGION-Ib)
Study ID: NCT00942604
Brief Summary: The purpose of this study is to determine whether topical application of PEP005 is effective for the treatment of actinic keratoses.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Burke Pharmaceutical Research, Hot Springs, Arizona, United States
Skin Surgery Medical Group Inc., San Diego, California, United States
Atlanta Dermatology, Vein & Research Center, LLC, Alpharetta, Georgia, United States
Altman Dermatology Associates, Arlington Heights, Illinois, United States
Glazer Dermatology, Buffalo Grove, Illinois, United States
Deaconess Clinic Downtown, Evansville, Indiana, United States
Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, United States
Skin Specialists, PC, Omaha, Nebraska, United States
Karl G. Heine Dermatology, Henderson, Nevada, United States
Group Health Associates, Cincinnati, Ohio, United States
DermResearch, Inc., Austin, Texas, United States
Suzanne Bruce and Associates, PA, The Center for Skin Research, Houston, Texas, United States
Dermatology Clinical Research Center of San Antonio, San Antonio, Texas, United States
Dermatology Associates of Tyler, Tyler, Texas, United States
Dermatology Research Center, Inc., Salt Lake City, Utah, United States
The Education and Research Foundation, Lynchburg, Virginia, United States
Virginia Clinical Research, Inc, Norfolk, Virginia, United States